Steven Lin
UT MD Anderson · M.D. Anderson Cancer Center · Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven Lin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07843537 · MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label StudyM.D. Anderson Cancer Center · not yet recruiting · Thoracic Cancer · principal investigator
- Ph2NCT07597070 · Universal Immunization to Fortify Immunotherapy Efficacy and ResponseUniversity of Florida · recruiting · Stage 4 NSCLC · principal investigator
- Ph1NCT06414902 · 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal CancerM.D. Anderson Cancer Center · recruiting · Esophageal Cancer · principal investigator
- Ph2NCT05632809 · REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)M.D. Anderson Cancer Center · recruiting · Lung Cancer · principal investigator
- N/ANCT05394766 · Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of HypertensionStanford University · completed · Hypertension · principal investigator
- Ph1NCT02389751 · Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal CancerM.D. Anderson Cancer Center · completed · Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasm of the Cervical Esophagus, Malignant Neoplasm of the Thoracic Esophagus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 100 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinomaU54CA274220 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2026 · $306,002 awarded in 2026Same name and institution; not confirmed by an ID
- Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery ApproachesU01CA216468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2021 · $596,334 awarded in 2021Same name and institution; not confirmed by an ID
- Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte InfusionR21CA240881 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2021 · $176,175 awarded in 2021Same name and institution; not confirmed by an ID
- Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer ImmunotherapyR21CA241001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2020 · $174,000 awarded in 2020Same name and institution; not confirmed by an ID
- DOES OLANZAPINE INHIBIT THE SECRETORY RESPONSE TO INSULIN RESISTANCE?M01RR000070 · NCRR · STANFORD UNIVERSITY · fiscal years 2008 · $21,503 awarded in 2008Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT02389751
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 08:41 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Respir Med · 2021486 citationsRCR 24.7
- 272 citationsRCR 16.9
- Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.J Immunother Cancer · 2020256 citationsRCR 10.1
- 217 citationsRCR 17.7
- Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.JAMA Oncol · 2017129 citationsRCR 4.6
- Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.J Thorac Oncol · 2020123 citationsRCR 4.8
- Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys · 201872 citationsRCR 3.3
- Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.J Thorac Oncol · 200855 citationsRCR 1.1
- Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.Int J Radiat Oncol Biol Phys · 201352 citationsRCR 1.7
- Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.Int J Clin Pharm · 202048 citationsRCR 1.6